Your Tests Are 'Normal'. So Why Do You Still Feel Like This?

The standard NHS thyroid test measures TSH — thyroid-stimulating hormone — a signal sent from the brain to the thyroid gland. It is a useful initial screen. It is not a full picture of thyroid function. And in two of the most common presentations we see, it can appear reassuring while significant dysfunction goes undetected.

The first is T4-to-T3 conversion failure. The thyroid produces T4 — an inactive storage hormone — which must be converted in peripheral tissues to T3, the active form that powers metabolism, cognition, mood, and energy production. In a significant proportion of people, this conversion is impaired — by chronic stress, gut inflammation, nutrient deficiencies, or genetic variants affecting the DIO2 enzyme. TSH can be entirely normal while this conversion failure is occurring. The person feels hypothyroid. The blood test says otherwise.

The second is Hashimoto's thyroiditis — the most common autoimmune condition in women, and almost certainly the most underdiagnosed. In Hashimoto's, the immune system has mounted an attack against the thyroid gland, generating antibodies — specifically anti-TPO and anti-TG — that drive chronic inflammation and progressive tissue damage. In the early and middle stages, TSH often remains in range. The GP reports a normal result. But the antibodies are elevated. The inflammation is ongoing. And the person is told there is nothing wrong.

This is the critical gap: Hashimoto's is not primarily a thyroid condition. It is an immune condition. Treating the thyroid — through medication alone — does not address the immune dysfunction driving the attack. This is why many people on levothyroxine continue to feel unwell. The hormone is being replaced. The autoimmune process remains unaddressed.

Investigation begins with a detailed case review: your full history, timeline, menstrual and hormonal pattern, symptom progression, prior test results, and medication history. Testing is then ordered to confirm what the clinical picture suggests — not applied as a generic package.

For thyroid and Hashimoto's presentations, testing typically includes some or all of the following: a full thyroid panel (Free T4, Free T3, Reverse T3, TSH, anti-TPO and anti-TG antibodies); cortisol and adrenal function; essential nutrient status (selenium, zinc, ferritin, iron saturation, B12, vitamin D); gut microbiome and intestinal permeability markers where indicated; sex hormone panel where perimenopause or cycle irregularity is a feature; and methylation markers where poor nutrient utilisation is suspected.

The goal is not a set of results in isolation. It is a coherent account of what is driving the symptoms — and a clear, sequenced protocol to address it.

This is the question most Hashimoto's clients arrive with — and the one that standard medicine rarely answers with any optimism. The evidence, and documented clinical experience, tells a different story.

Hashimoto's remission — defined as a significant and sustained reduction in TPO antibodies, resolution of active symptoms, and stabilisation of thyroid function — is a realistic clinical goal when the immune triggers are identified and addressed. Medication alone is not designed to do this, because it replaces hormone without addressing the immune driver. It involves identifying and removing the drivers of the autoimmune attack: the gut permeability that is allowing food proteins to trigger immune reactivity; the nutrient deficiencies that are impairing immune regulation and thyroid conversion; the chronic inflammation that is keeping the attack active; and in some cases, the toxic burden or chronic infections that are amplifying the whole picture.

The timeline varies. In Paul's clinical experience — which includes multiple documented Hashimoto's cases with measured antibody reduction — many clients report meaningful symptom improvement within the first weeks of targeted intervention. Significant antibody reduction has been observed over a three-to-twelve-month programme. People already on levothyroxine can and do recover — not by stopping medication, but by addressing the root cause that the medication was never designed to touch.